Trial reportFrontiers in cardiovascular medicine2026
Efficacy and safety of Lingbao Huxin Dan in the treatment of sick sinus syndrome: a randomized, single-blind, placebo-controlled, crossover trial.
Trial report in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Permanent pacemaker implantation is the standard treatment for symptomatic sick sinus syndrome (SSS), but it does not reverse the underlying sinus node dysfunction. Lingbao Huxin Dan (LBHXD) may benefit patients with bradyarrhythmia. However, robust clinical evidence regarding its efficacy and safety in patients with SSS, particularly those with pacemakers, is lacking. Methods: A randomized, crossover trial was conducted. Thirty patients with SSS and implanted DDD pacemakers were enrolled and randomly assigned to one of two treatment sequences: LBHXD followed by placebo, or placebo followed by LBHXD. Each treatment period lasted 4 weeks, separated by a 2-week washout interval. Results: 25 patients completed the trial. Following propensity score matching, 17 patients were included in the final analysis. Compared to the placebo phase, LBHXD administration resulted in a significantly greater reduction in AP% (38.99% ± 20.67% vs. 48.03% ± 21.95%, Conclusion: Adjunctive therapy with Lingbao Huxin Dan can effectively reduce atrial pacing dependency, improve heart rate variability, and increase heart rate in patients with SSS and pacemakers, demonstrating a favorable safety profile. These findings suggest that LBHXD may enhance intrinsic sinoatrial node function and autonomic regulation, supporting its potential role as a complementary therapy in an integrative medicine approach to managing SSS. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=187346, Chinese Clinical Trial Registry ChiCTR2300067497.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.